On Monday, Insulet got an upgrade to its Relative Strength (RS) Rating, from 62 to 73.
This unique rating identifies market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating as they begin their largest climbs. See if Insulet can continue to show renewed price strength and clear that threshold.
Can You Really Time The Stock Market?
Insulet is trying to complete a cup without handle with a 223.56 buy point. See if the stock can break out in heavy trading.
Earnings growth increased last quarter from 169% to 217%. But revenue gains fell from 38% to 23%.
The company holds the No. 8 rank among its peers in the Medical-Products industry group. LeMaitre Vascular, Globus Medical and Lantheus Holdings are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
